Circumventing immunogenicity in the development of therapeutic antibodies

IDrugs

Volumn 12, Issue 4, 2009, Pages 233-237

  Holgate, Robert G E ^a   Baker, M P ^a  

^a Antitope Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ANTHIM; ANTIBODY; EPITOPE; ETI 204; INFLIXIMAB; MONOCLONAL ANTIBODY J591; RITUXIMAB; THROMBOVIEW; UNCLASSIFIED DRUG; VB6 845;

DRUG SAFETY; EX VIVO STUDY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; NONHUMAN; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; DRUG DESIGN; DRUG HYPERSENSITIVITY; EPITOPES, T-LYMPHOCYTE; HUMANS;

EID: 64349088506     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. Hwang WY, Foote J: Immunogenicity of engineered antibodies. Methods (2005) 36(1):3-10.
2. Baker MP, Jones TD: Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel (2007) 10(2):219-227.
3. Perry LC, Jones TD, Baker MP: New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R&D (2008) 9(6):385-396.